Undisclosed KRAS G12D inhibitor / BMS - LARVOL DELTA

Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models. (PubMed, Sci Transl Med) - "This combination induces durable immune memory in immunogenic models but not in nonimmunogenic settings. Our findings underscore key differences between KRAS G12D and G12C mutations in shaping lung cancer biology, reveal distinct resistance dynamics under long-term targeted therapy, and uncover immune-mediated mechanisms specific to KRASG12D inhibition with direct clinical and translational relevance."

Journal • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS

Dr Jänne on the Investigation of RMC-6291 in KRAS G12C-Mutated Solid Tumors (OncLive) - P1/b | N=117 | (NCT05462717) | Sponsor: Revolution Medicines, Inc. | "Pasi A. Janne, MD, PhD, discusses the mechanism of action of the novel KRAS G12C RAS(ON) inhibitor RMC-6291, which is being evaluating for the treatment of patients with KRAS-mutated solid tumors."

P1 data • Video

KRAS G12C Inhibitors: Durability of Response, Efficacy in Combination, in NSCLC (THE ASCO POST) - ''In the current pooled analysis with longer follow-up, adagrasib demonstrated durable clinical activity, with a median overall survival of 14.1 months and approximately one in three patients alive at 2 years,' said Shirish Gadgeel, MBBS....A confirmatory phase III study-KRYSTAL-12-is evaluating adagrasib vs docetaxel in previously treated patients in North America, Europe, Asia, and Australia."

Media quote

#Targets23 Dr. @AlexSpiraMDPhD presents early look at RMC-6236, a first-in-class RAS(ON) inhibitor in #KRAS tumors. Safety data very reassuring and example of response in KRAS G12D pancreatic cancer and KRAS G12D NSCLC! Huge unmet need, very exciting - await data at #ESMO23!